NantKwest, Inc.(NK)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NK NantKwest, Inc.

未开盘 03-09 16:00:00 EST

32.49

+0.00

0.00%

最高32.49	最低32.49	成交量0.00
今开32.49	昨收32.49	日振幅0.00%
总市值35.53亿	流通市值13.37亿	总股本1.09亿
成交额0.00	换手率0.00%	流通股本4,116万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"NK","market":"US","secType":"STK","nameCN":"NantKwest, Inc.","latestPrice":32.49,"timestamp":1615323600000,"preClose":32.49,"halted":8,"volume":0,"delay":0,"floatShares":41155657,"shares":109344573,"eps":-0.89215,"marketStatus":"未开盘","marketStatusCode":0,"change":0,"latestTime":"03-09 16:00:00 EST","open":32.49,"high":32.49,"low":32.49,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.89215,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1735290000000},"symbolChange":{"newSymbol":"IBRX","executeDate":"2021-03-10"},"adr":0,"listingDate":1438056000000,"adjPreClose":32.49,"adrRate":0,"volumeRatio":0},"requestUrl":"/m/hq/s/NK","defaultTab":"news","newsList":[{"id":"2283276808","title":"100%癌症缓解率，NK细胞“杀疯了”","url":"https://stock-news.laohu8.com/highlight/detail?id=2283276808","media":"虎嗅","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2283276808?lang=zh_cn&edition=full","pubTime":"2022-11-16 17:15","pubTimestamp":1668590114,"startTime":"0","endTime":"0","summary":"细胞免疫疗法“大家庭”又有好消息了","market":"hk","thumbnail":"https://img.huxiucdn.com/article/cover/202211/16/170738838839.jpg?imageView2/1/w/720/h/405/|imageMogr2/strip/interlace/1/quality/85/format/jpg","type":0,"news_type":0,"thumbnails":["https://img.huxiucdn.com/article/cover/202211/16/170738838839.jpg?imageView2/1/w/720/h/405/|imageMogr2/strip/interlace/1/quality/85/format/jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.huxiu.com/article/715943.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_huxiu","symbols":["NK"],"gpt_icon":0},{"id":"2281696170","title":"兆科眼科-B(06622)：以ZKY001用于治疗TPRK的第II期临床试验、用于治疗翼状肉的第II期临床试验及用于治疗NK的IIT完成患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2281696170","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2281696170?lang=zh_cn&edition=full","pubTime":"2022-11-08 17:16","pubTimestamp":1667898999,"startTime":"0","endTime":"0","summary":"智通财经APP讯，兆科眼科-B 发布公告，公司其中一种核心候选药物ZKY001的三项临床试验完成患者入组。该试验涉及10个中心，入组共120名患者。用于治疗翼状胬肉的第II期临床试验于2022年10月31日入组最后一名患者。ZKY001对于促进角膜伤口癒合的应用范围广泛，有望用于多种角膜癒合适应症。公司目前正在发掘ZKY001四种适应症，包括CED、TPRK、翼状胬肉及NK。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/825987.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1587","BK1576","BK1583","NK","06622","BK1191","BK1141","BK1574","03347"],"gpt_icon":0},{"id":"2278674157","title":"血液科一区顶刊:流式细胞术急性淋巴细胞白血病的预后选题思路","url":"https://stock-news.laohu8.com/highlight/detail?id=2278674157","media":"小欧聊科研","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2278674157?lang=zh_cn&edition=full","pubTime":"2022-10-26 09:18","pubTimestamp":1666747117,"startTime":"0","endTime":"0","summary":"发现了NK细胞分析作为预测急性淋巴细胞白血病患者临床结果的诊断工具的好处，并强调了同种异体NK细胞输注预防急性淋巴细胞复发的临床潜力。由于CD56dimDNAM-1NK细胞是细胞毒性最大的NK细胞部分，研究结果表明，急性淋巴细胞白血病患者的NK细胞成熟缺陷。细胞因子，裂解颗粒和CD107a的表达增加（图4）表明急性淋巴细胞白血病患者的PBMC NK细胞过度活化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina_symbol","url":"https://cj.sina.cn/article/normal_detail?url=https://k.sina.cn/article_7745966052_1cdb20fe400101cv6l.html","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.extra-info, .source{#sourceStyle#;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://cj.sina.cn/article/normal_detail?url=https://k.sina.cn/article_7745966052_1cdb20fe400101cv6l.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina_symbol","symbols":["LU1201861165.SGD","BK4574","BK4555","LU0208291251.USD","GM","BK4559","ALL","LU0070302665.USD","BK4533","LU0648000940.SGD","BK4099","MRD","BK4107","BK4135","CNS","LU0130103400.USD","BK4566","LU0320765489.SGD","BK4561","NK"],"gpt_icon":0},{"id":"2267828585","title":"基石药业(02616.HK)「择捷美」治疗复发难治性结外NK/T细胞淋巴瘤新适应症上市申请获内地受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2267828585","media":"AAFN","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2267828585?lang=zh_cn&edition=full","pubTime":"2022-09-13 16:57","pubTimestamp":1663059445,"startTime":"0","endTime":"0","summary":"基石药业  公布，继III期和IV期非小细胞肺癌适应症后，「择捷美」在内地申报第三项新适应症上市申请，获中国国家药品监督管理局受理并纳入优先审评，有望成为全球首个获批用於复发或难治性结外NK/T细胞淋巴瘤的肿瘤免疫治疗药物。「择捷美」先後被美国食品药品监督管理局和国家药品监督管理局药品审评中心，授予突破性疗法认定和纳入突破性治疗药物，用於治疗成人复发或难治性结外NK/T细胞淋巴瘤。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1213081&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks","symbols":["NK","02616"],"gpt_icon":0},{"id":"2267056302","title":"肠道微生物与癌症：远没你想的那么简单","url":"https://stock-news.laohu8.com/highlight/detail?id=2267056302","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2267056302?lang=zh_cn&edition=full","pubTime":"2022-09-13 11:39","pubTimestamp":1663040353,"startTime":"0","endTime":"0","summary":"肠道微生物与癌症近年来，有多种细菌被发现通过危害肠道微生物生态进而促进大肠癌的发病。事实上肠道内的微生物会通过几种标志性机制影响宿主免疫和对癌症治疗的反应。而不同年龄的散发性大肠癌，其肠道微生物组的特征也可能有所差异。这是由全身免疫成分与炎症标志物、组织免疫和肿瘤免疫以及肠道和肿瘤微生物群之间的动态相互作用介导的。不同健康状况下肠道与组织中微生物的影响。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"fenghuang_stock","url":"https://tech.ifeng.com/c/8JGvVKl8yX6","rn_cache_url":null,"customStyle":"","selectors":"article, body","filters":"","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://tech.ifeng.com/c/8JGvVKl8yX6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fenghuang_stock","symbols":["BK4509","NK","TME","NGS","BK4548","BK4535","BK4179","BK4571","BK4552","BK4108","BK4563","BK4531","BK4526","BK4565"],"gpt_icon":0},{"id":"2267709433","title":"基石药业-B(02616)：舒格利单抗治疗复发或难治性结外NK/T细胞淋巴瘤的新适应症上市申请获国家药监局受理并纳入优先审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2267709433","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2267709433?lang=zh_cn&edition=full","pubTime":"2022-09-13 08:10","pubTimestamp":1663027821,"startTime":"0","endTime":"0","summary":"智通财经APP讯，基石药业-B 发布公告，舒格利单抗治疗复发或难治性结外NK/T细胞淋巴瘤的新适应症上市申请获中国国家药品监督管理局受理并纳入优先审评。此次舒格利单抗治疗R/R ENKTL的新适应症上市申请获得受理是基于GEMSTONE-201研究，该研究旨在评估舒格利单抗作为单药治疗成人R/R ENKTL的有效性和安全性。舒格利单抗在R/R ENKTL患者中耐受性和安全性良好，未发现新的安全性信号。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/790855.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","NK","02616"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.nantkwest.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.026},{"period":"1month","weight":0.0011},{"period":"3month","weight":0.0523},{"period":"6month","weight":0.105},{"period":"1year","weight":0.262},{"period":"ytd","weight":0.2652}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"NantKwest, Inc.于2002年10月7日在伊利诺伊州ZelleRx Corporation公司的名义下注册成立，于2010年1月22日，公司更名为Conkwest股份有限公司。公司是一家从事某些特定操作的生物技术公司，总部位于加的夫由这海，加州卡尔弗城。公司的商业性在于开发直接用于治疗各种临床病症的免疫治疗剂。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.088396},{"month":2,"riseRate":0.5,"avgChangeRate":0.014909},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.030987},{"month":4,"riseRate":0.6,"avgChangeRate":-0.007712},{"month":5,"riseRate":0.4,"avgChangeRate":0.134114},{"month":6,"riseRate":0.4,"avgChangeRate":0.306542},{"month":7,"riseRate":0.6,"avgChangeRate":0.071269},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.121349},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.084901},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.135977},{"month":11,"riseRate":0.833333,"avgChangeRate":0.203524},{"month":12,"riseRate":0.5,"avgChangeRate":0.187796}],"exchange":"NASDAQ","name":"NantKwest, Inc.","nameEN":"NantKwest"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"NantKwest, Inc.(NK)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供NantKwest, Inc.(NK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"NantKwest, Inc.,NK,NantKwest, Inc.股票,NantKwest, Inc.股票老虎,NantKwest, Inc.股票老虎国际,NantKwest, Inc.行情,NantKwest, Inc.股票行情,NantKwest, Inc.股价,NantKwest, Inc.股市,NantKwest, Inc.股票价格,NantKwest, Inc.股票交易,NantKwest, Inc.股票购买,NantKwest, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"NantKwest, Inc.(NK)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供NantKwest, Inc.(NK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}